Refreshing results…
LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses
UploadCombinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Download from doi.orgMissing publications? Search for publications with a matching author name.